136 related articles for article (PubMed ID: 25118375)
21. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
Jiang L; Fan R; Sun S; Fan P; Su W; Zhou Y; Gao F; Xu F; Kong W; Jiang C
Vaccine; 2015 Nov; 33(48):6596-603. PubMed ID: 26529072
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of multiple clinical enterovirus 71 isolates and evaluation of cross protection of inactivated vaccine strain FY-23 K-B in vitro.
Yang T; Li H; Yue L; Song X; Xie T; Ma S; Meng H; Zhang Y; He X; Long R; Yang R; Luo F; Xie Z; Li Q
Virol J; 2017 Oct; 14(1):206. PubMed ID: 29073897
[TBL] [Abstract][Full Text] [Related]
23. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development.
Wu SC; Liu CC; Lian WC
Vaccine; 2004 Sep; 22(29-30):3858-64. PubMed ID: 15364432
[TBL] [Abstract][Full Text] [Related]
24. An adult gerbil model for evaluating potential coxsackievirus A16 vaccine candidates.
Yao PP; Miao ZP; Xu F; Lu HJ; Sun YS; Xia Y; Chen C; Yang ZN; Xia SC; Jiang JM; Hu CG; Mao ZA; Gao M; Xu ZY; Ying HN; Yao CH; Zhu ZY; Zhu HP; Xiang HQ
Vaccine; 2019 Aug; 37(36):5341-5349. PubMed ID: 31351798
[TBL] [Abstract][Full Text] [Related]
25. Enterovirus-Specific Anti-peptide Antibodies.
Poh CL; Kirk K; Chua HN; Grollo L
Methods Mol Biol; 2015; 1348():341-50. PubMed ID: 26424285
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of three detection methods for neutralizing antibodies induced by Coxsackievirus A16 vaccine].
Yi D; Sun L; Chen Q; Zhang N; Han J; Ye X; Su X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Mar; 29(3):287-91. PubMed ID: 23643087
[TBL] [Abstract][Full Text] [Related]
27. Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils.
Sun YS; Xia Y; Xu F; Lu HJ; Mao ZA; Gao M; Pan TY; Yao PP; Wang Z; Zhu HP
Emerg Microbes Infect; 2022 Dec; 11(1):1994-2006. PubMed ID: 35787233
[TBL] [Abstract][Full Text] [Related]
28. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge.
Chung YC; Ho MS; Wu JC; Chen WJ; Huang JH; Chou ST; Hu YC
Vaccine; 2008 Mar; 26(15):1855-62. PubMed ID: 18329759
[TBL] [Abstract][Full Text] [Related]
29. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.
Lin YL; Yu CI; Hu YC; Tsai TJ; Kuo YC; Chi WK; Lin AN; Chiang BL
Vaccine; 2012 Feb; 30(7):1305-12. PubMed ID: 22214888
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
31. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice.
Wu TC; Wang YF; Lee YP; Wang JR; Liu CC; Wang SM; Lei HY; Su IJ; Yu CK
J Virol; 2007 Oct; 81(19):10310-5. PubMed ID: 17626076
[TBL] [Abstract][Full Text] [Related]
32. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys.
Dong C; Liu L; Zhao H; Wang J; Liao Y; Zhang X; Na R; Liang Y; Wang L; Li Q
Vaccine; 2011 Aug; 29(37):6269-75. PubMed ID: 21722686
[TBL] [Abstract][Full Text] [Related]
33. [The effects of inoculation route and adjuvant type on the immunizing potency of CVB3 VP1 protein].
Wen C; Gao ZY; Lan JM; Yan LJ; Chuai X; Li J; Li W; Wang YX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Oct; 27(10):1086-9. PubMed ID: 21968309
[TBL] [Abstract][Full Text] [Related]
34. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
Liu CC; Chow YH; Chong P; Klein M
Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial.
Hung MC; Cho CY; Chen CJ; Lai CC; Wu KG
Vaccine; 2019 Sep; 37(37):5559-5566. PubMed ID: 31399275
[TBL] [Abstract][Full Text] [Related]
36. [Study on adjuvant effect of oral recombinant subunit vaccine formulated with chitosan against human enterovirus 71].
Zhang S; Zhang FS; Li AQ; Liu L; Wu W; Li C; Zhang QF; Liang MF; Li DX
Bing Du Xue Bao; 2014 May; 30(3):221-5. PubMed ID: 25118374
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
Huang LM; Chiu CH; Chiu NC; Lin CY; Li MT; Kuo TY; Weng YJ; Hsieh EF; Tai IC
Vaccine; 2019 Mar; 37(13):1827-1835. PubMed ID: 30803843
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice.
Mao Q; Dong C; Li X; Gao Q; Guo Z; Yao X; Wang Y; Gao F; Li F; Xu M; Yin W; Li Q; Shen X; Liang Z; Wang J
PLoS One; 2012; 7(9):e46043. PubMed ID: 23029378
[TBL] [Abstract][Full Text] [Related]
39. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge.
Shen C; Liu Q; Zhou Y; Ku Z; Wang L; Lan K; Ye X; Huang Z
Vaccine; 2016 Sep; 34(41):5005-5012. PubMed ID: 27562093
[TBL] [Abstract][Full Text] [Related]
40. Intradermal injection of a fractional dose of an inactivated HFMD vaccine elicits similar protective immunity to intramuscular inoculation of a full dose of an Al(OH)
Li M; Duan Y; Yang X; Yang Q; Pang B; Wang Y; Ren T; Wang X; Zhao Z; Liu S
Vaccine; 2017 Jun; 35(30):3709-3717. PubMed ID: 28576572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
